GlassScriptPhysician profile
Laylan Shali
NPI 1538629787
$928.47
in general payments reported to CMS, 2019-2025
11 companies · $928 in 2025
The $928 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.46 |
| Education | $270.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $314.68 | 2025 | Ensite, Optis, Coroflow |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $184.18 | 2025 | Lifevest |
| Boston Scientific Corporation | $163.13 | 2025 | Avvigo Guidance System |
| E.R. Squibb & Sons, L.L.C. | $68.69 | 2025 | Camzyos |
| Atricure, INC. | $53.50 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Amgen INC. | $40.51 | 2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $29.87 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $23.72 | 2025 | Uptravi, Opsumit |
| Pfizer INC. | $17.23 | 2025 | |
| Daxor Corporation | $16.91 | 2025 | Bva-100 |
| Scpharmaceuticals INC. | $16.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laylan Shali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.